Targets › ZNT1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Aug 2027.
Zinc ion:proton antiporter that could function at the plasma membrane mediating zinc efflux from cells against its electrochemical gradient protecting them from intracellular zinc accumulation and toxicity. Alternatively, could prevent the transport to the plasma membrane of CACNB2, the L-type calcium channels regulatory subunit, through a yet to be defined mechanism. (UniProt, Q9Y6M5)
Open in Phaseline: the race on ZNT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Anhui Provincial Hospital | Oral elemental zinc supplementation Zinc supplementation (cofactor for immune cell function) | ZNT1, ZNT2 | Phase 2 | Hepatocellular Carcinoma | Aug 2027 |
Hepatocellular Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.